Us2.ai
Overview
Us2.ai is an FDA-cleared AI software platform that revolutionizes echocardiogram analysis by providing fully automated, zero-click structured reports. It connects to ultrasound devices and PACS, processing echocardiograms in real-time to deliver comprehensive measurements, disease detection, and clinical findings. The platform is designed to minimize manual interventions, reduce reporting time by up to 70%, and improve consistency and accuracy in cardiac diagnostics. Us2.ai supports the detection of a wide array of heart-related conditions, including cardiac amyloidosis, heart failure, aortic stenosis, and pulmonary hypertension, aligning with international guidelines. It also offers unique capabilities for retrospective analysis of archived echocardiograms to uncover undetected diseases at a population level.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Fully automated echocardiography analysis
- Zero-click structured reports
- Real-time processing of echocardiograms
- Automated disease detection (e.g., cardiac amyloidosis, heart failure, aortic stenosis, pulmonary hypertension)
- Comprehensive automated measurements (2D, Doppler, M-mode, strain analysis)
- Integration with PACS, CVIS, EMR, and ultrasound devices (DICOM, HL7)
- Editable AI outputs and annotations
- Guideline-based reporting (international guidelines)
- Retrospective echo analysis and EHR mining
- Enterprise-grade security and compliance (ISO 27001:2022, MDSAP)
Use Cases
- Automated echocardiogram interpretation and reporting
- Detection and diagnosis of various cardiac conditions
- Population-level disease screening from archived echocardiograms
- Improving efficiency and throughput in echo labs
- Supporting clinical decision-making for cardiologists and sonographers
- End-to-end clinical trial echo analysis (Core Lab Solutions)
What Physicians Need to Know
Leverage Us2.ai to significantly reduce echocardiogram analysis and reporting time, freeing up valuable clinician time for patient interaction and complex cases. The fully automated, zero-click workflow enhances consistency and reproducibility of measurements, which is crucial for serial follow-up and population health initiatives. Utilize its capability for early detection of conditions like cardiac amyloidosis and heart failure, even from archived studies, to improve patient outcomes. The platform's support for novice operators with AI-assisted POCUS can expand access to cardiac screening in various care settings. Always review the editable AI outputs and maintain final clinical sign-off, using the AI as a powerful decision support tool.
Us2.ai is designed for seamless integration into existing clinical workflows, connecting with any ultrasound device (GE, Philips, Siemens, handheld POCUS), Picture Archiving and Communication Systems (PACS), Cardiovascular Information Systems (CVIS), and Electronic Medical Records (EMR) via standard DICOM routing, HL7, and DICOM SR. Strategic partnerships include Merge Cardio, Aidoc (integrating Us2.ai into its aiOSu2122 platform), deepc (via deepcOSu00ae), and Fujifilm (for its LISENDO 880 ultrasound system), enabling a comprehensive, end-to-end intelligence layer for cardiac care.
Details
| Category | Cardiology AI |
| Pricing | Contact for pricing — Volume-based pricing model; installation and associated costs vary by configuration |
| Deployment | Cloud or on-premise deployment options |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
1 AI-estimated Us2.ai has received FDA clearance for Us2.v1 (September 2021) and Us2.v2 (April 2024), transforming cardiovascular ultrasound analysis with fully automated decision support for echocardiography, including 45 automated echo parameters and cardiac amyloidosis detection. |
| Integrations | |
| EHR | Not specified |
| Specialties | Cardiology, Critical Care, Emergency Medicine |
What the Web Says
Us2.ai is an AI-powered echocardiography analysis software that aims to automate and streamline the interpretation of echocardiograms, providing comprehensive, guideline-based reports with zero clicks. Physicians and sonographers have reported positive experiences, noting improvements in measurement accuracy, workflow efficiency, and a reduction in administrative burden. The platform is FDA-cleared and CE marked, and it integrates with existing hospital infrastructure.
Overall: PositiveStrengths
- Enhances measurement accuracy and consistency
- Improves workflow efficiency and reduces reporting time significantly (up to 70% faster)
- Reduces sonographer fatigue and allows them to focus on image acquisition quality
- Provides fully automated, comprehensive structured reports with zero clicks
- Vendor-neutral and integrates with various ultrasound devices, PACS, CVIS, and EMR systems
- Aids in early detection of conditions like cardiac amyloidosis and heart failure
Limitations
- Initial concerns about AI replacing clinical roles, though this is being addressed by framing AI as a supportive tool
- Potential for bias in reviews on platforms like G2 and Capterra, making it challenging to find unbiased feedback
- Some users on Reddit express general skepticism about AI accuracy and the need for human oversight
- The taxonomy on some review sites can be rigid, potentially not fitting newer tools
- Lack of extensive independent user reviews on platforms like G2 and Capterra specifically for Us2.ai
Based on reviews from: Us2.ai, G2, Reddit, Slashdot, The Imaging Wire
Last updated: 2026-07-20
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Us2.ai
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for Us2.ai.
AI Echocardiography the future of echo with Us2 connect
Frequently Asked Questions
Compare Us2.ai
VS
VS
VS
VS
